Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Song

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) AnalysisArleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia|March 9, 2026
Heterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changesNicholas Chornenki, Afraa Fadul, Analiza Supan, et al.
Blood Neoplasia|May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian reportMartha L Louzada, Donna Reece, Christopher P Venner, et al.
Leukemia & Lymphoma|February 8, 2022
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trialNizar J Bahlis, David S Siegel, Gary J Schiller, et al.
Blood Cancer Journal|August 27, 2023
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysisArleigh McCurdy, Hira Mian, Richard LeBlanc, et al.
Transplantation and Cellular Therapy|July 6, 2024
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group DatabaseChristopher P Venner, Peter Duggan, Kevin Song, et al.
Frontiers in Oncology|March 7, 2022
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective AnalysisHira Mian, Christine Eisfeld, Christopher P Venner, et al.
Blood Cancer Journal|July 20, 2023
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysisArleigh McCurdy, Hira Mian, Richard LeBlanc, et al.
Blood Cancer Journal|September 5, 2023
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseJulie Côté, Richard LeBlanc, Hira Mian, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 28, 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical DatabaseJulia Varghese, Christopher P Venner, Martha Louzada, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|March 28, 2025
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) AnalysisArleigh McCurdy, Engin Gul, Donna Reece, et al.
Blood Neoplasia|March 9, 2026
Heterogeneous survival outcomes in molecularly defined acute myeloid leukemia with myelodysplasia-related changesNicholas Chornenki, Afraa Fadul, Analiza Supan, et al.
Blood Neoplasia|May 25, 2026
Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian reportMartha L Louzada, Donna Reece, Christopher P Venner, et al.
Leukemia & Lymphoma|February 8, 2022
Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trialNizar J Bahlis, David S Siegel, Gary J Schiller, et al.
Blood Cancer Journal|August 27, 2023
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysisArleigh McCurdy, Hira Mian, Richard LeBlanc, et al.
Transplantation and Cellular Therapy|July 6, 2024
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group DatabaseChristopher P Venner, Peter Duggan, Kevin Song, et al.
Frontiers in Oncology|March 7, 2022
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective AnalysisHira Mian, Christine Eisfeld, Christopher P Venner, et al.
Blood Cancer Journal|July 20, 2023
Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysisArleigh McCurdy, Hira Mian, Richard LeBlanc, et al.
Blood Cancer Journal|September 5, 2023
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseJulie Côté, Richard LeBlanc, Hira Mian, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 28, 2025
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical DatabaseJulia Varghese, Christopher P Venner, Martha Louzada, et al.
Pageof 10